Results 11 to 20 of about 2,383,672 (201)
Chronic lymphocytic leukemia, the most common adult leukemia worldwide, is considered an indolent but incurable non-Hodgkin lymphoma. Leukemia cutis is an uncommon manifestation of chronic lymphocytic leukemia.
Ali Raufi +4 more
doaj +2 more sources
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials [PDF]
This study investigated the impact of comorbidity in 555 patients with chronic lymphocytic leukemia enrolled in two trials of the German Chronic Lymphocytic Leukemia Study Group on first-line treatment with fludarabine plus cyclophosphamide, fludarabine,
Valentin Goede +11 more
doaj +2 more sources
Limited data are available about the underlying causes of hemophagocytic lymphohistiocytosis (HLH) in adults. We collected and analyzed the data of 555 cases of adult HLH.
Yi Miao +30 more
doaj +1 more source
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world with great heterogeneity. Pyroptosis has recently been recognized as an inflammatory form of programmed cell death (PCD) and shares a close relationship with apoptosis ...
Yeqin Sha +36 more
doaj +1 more source
Targeting Bruton’s Tyrosine Kinase in CLL
Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.
Inhye E. Ahn, Jennifer R. Brown
doaj +1 more source
AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression
The enzyme activation-induced cytidine deaminase (AID) initiates somatic hypermutation (SHM) and class switch recombination (CSR) of immunoglobulin (Ig) genes, critical actions for an effective adaptive immune response.
Pablo Oppezzo +2 more
doaj +1 more source
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small ...
Susan M. O’Brien +6 more
doaj +1 more source
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. [PDF]
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia ...
Di Bernardo, M. C. +182 more
core +5 more sources
Efficient and accurate high-throughput DNA sequencing of the adaptive immune receptor repertoire (AIRR) is necessary to study immune diversity in healthy subjects and disease-related conditions.
Stefano Vergani +7 more
doaj +1 more source
T LYMPHOCYTE SUBSETS STUDIED IN A PATIENT WITH TWO ASSOCIATED HEMATOLOGIC NEOPLASIAS – CHRONIC LYMPHOCYTIC LEUKEMIA B AND CHRONIC MYELOID LEUKEMIA [PDF]
Quantification of various cellular subpopulations facilitates the monitoring of hematological diseases, including chronic lymphocytic leukemia. Variations in the proportions of regulatory T cells in peripheral blood have been described in patients with
Georgiana Ene +3 more
doaj +1 more source

